Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

July 15, 2026 3:30 AM EDT

Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down SyndromeAssociated Alzheimers Disease (DS-AD)

Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA)

Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimers Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA)

Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN5288 in Alzheimers Patients

CAMBRIDGE, Mass.--(BUSINESS... More